San Diego, CA, United States
San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Tocagen Inc. | Date: 2017-02-01

The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.


Patent
Tocagen Inc. | Date: 2015-03-25

The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.


Patent
Tocagen Inc. | Date: 2017-04-26

The disclosure provide cell lines and methods for the production of vectors and viral particles useful in gene therapy.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 224.74K | Year: 2014

DESCRIPTION (provided by applicant): Molecular Imaging-Based Monitoring of Tumor-Selective Virus Replication Prodrug activator ('suicide') gene strategies using novel retroviral replicating vectors (RRV) have been developed for the treatment of high gradegliomas. The RRV transduced tumor cells produces more vector capable of initiating further infection events. This ability to spread has the potential to overcome one limitation previously observed with non-replicating vectors. These RRV agents are not directly cytolytic and spread specifically through the replicating cells of the tumor without direct tumor lysis. A second key limitation in the clini has been the inability to assay the extent of RVV spread in these poorly accessible, heterogeneous tumors. Wepropose to use Positron Emission Tomography (PET) as a non-invasive monitoring technique to track the spread of RRV and to use this information to appropriately time the oral administration of the prodrug to maximize tumor killing, or to identify RR


Patent
Tocagen Inc. | Date: 2015-09-02

Provided are methods and compositions useful for detecting viral infection or contamination in a biological sample.


The disclosure provides for one or more immunosuppressive components associated with retroviral replicating vectors (RRVs) that contribute to RRV tumor specificity and efficacy.


Patent
Tocagen Inc. | Date: 2014-09-04

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.


Patent
Tocagen Inc. | Date: 2014-05-09

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.


Patent
Tocagen Inc. | Date: 2016-02-04

The disclosure describes replication competent retroviral vectors (RCR) for gene therapy and gene delivery. The RCR includes an IRES sequence having 5-6As in A-bulge of the bifurcation region.


Patent
Tocagen Inc. | Date: 2013-12-20

This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Loading Tocagen Inc. collaborators
Loading Tocagen Inc. collaborators